Holen Sie sich die Stockscreener-App
76.57
3.71%
-2.8814
Schlusskurs vom Vortag:
$79.45
Offen:
$78.16
24-Stunden-Volumen:
353.98K
Relative Volume:
0.17
Marktkapitalisierung:
$12.59B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-25.19
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
-5.09%
1M Leistung:
-8.36%
6M Leistung:
+24.94%
1J Leistung:
+126.67%
1-Tages-Spanne:
$76.13
$79.04
1-Wochen-Bereich:
$76.46
$82.75
52-Wochen-Spanne:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.22 | 13.12B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.18 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.05 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.90 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance UK
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS) - Sahm
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell - MarketBeat
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Ionis Pharmaceuticals (IONS) Target Price Raised to $100 by Pipe - GuruFocus
Ionis presents new data on hereditary angioedema drug at AAAAI By Investing.com - Investing.com India
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN) - The Globe and Mail
Ionis presents new data on hereditary angioedema drug at AAAAI - Investing.com
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting - Business Wire
TD Asset Management Inc Sells 144,418 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Dana Investment Advisors Inc. Acquires Shares of 18,818 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS) - Seeking Alpha
Decoding Ionis Pharmaceuticals Inc (IONS): A Strategic SWOT Insi - GuruFocus
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 - Bitget
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook - The Globe and Mail
Olezarsen sNDA accepted by the FDA for Priority Review - marketscreener.com
IONS: Priority review for olezarsen accelerates launch plans amid robust pipeline and commercial momentum - TradingView
IONS: Priority review for olezarsen and robust pipeline set stage for major growth and global expansion - TradingView
FDA Grants Priority Review to Ionis Pharmaceuticals' Olezarsen A - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $77.00 - MarketBeat
Ionis Pharmaceuticals (IONS) Analyst Rating Update: Stifel Maint - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript - Insider Monkey
Needham Raises Ionis Pharmaceuticals (IONS) Price Target to $103 - GuruFocus
6 Analysts Have This To Say About Ionis Pharmaceuticals - Benzinga
Drug cutting pancreatitis attacks 85% gets speedy FDA review - Stock Titan
Ionis Pharmaceuticals Q4 Loss Of US$229 Million Tests Bullish Profitability Narrative - Sahm
Needham Maintains Buy on Ionis Pharmaceuticals (IONS) Feb 25, 2026 - Meyka
Morgan Stanley raises Ionis Pharmaceuticals price target on strong execution - Investing.com
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform - Investing.com Australia
Earnings call transcript: Ionis Pharmaceuticals Q4 2025 misses EPS forecast, stock drops - Investing.com Australia
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):